此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

rTMS 针对难治性抑郁症的神经连接和反思

2026年11月2日 更新者:Susan K. Conroy、Indiana University

重复经颅磁刺激腹内侧前额叶皮层以治疗难治性重度抑郁症的神经连接和沉思:一项试点研究

The goal of this clinical trial is to learn if Transcranial Magnetic Stimulation (TMS) to part of the brain called the ventromedial prefrontal cortex (VMPFC) can treat a symptom called rumination in adults with major depression that has not responded to at least one medication trial. The main question it aims to answer are:

Does TMS to the VMPFC change brain activity on functional magnetic resonance imaging (fMRI) during a negative self-referential processing task in adults with depression? Does TMS to the VMPFC affect rumination in adults with depression? Researchers will compare brain scans and rumination scores before, during, and immediately after TMS.

Participants will:

Undergo three functional MRI scans Undergo a course of 20 TMS treatments Respond to clinical questionnaires and complete a computer behavioral task

研究概览

地位

主动,不招人

详细说明

This will be a single-site, pilot, open-label, within-subject design study. 20 participants with treatment-resistant depression, defined as a failure to respond to at least one antidepressant medication trial within a current major depressive episode, will be recruited. Prior to intervention, participants will undergo self-report and clinician-administered assessments (in-person or virtual with both audio and video on using secure health telecommunication method), as well as a fMRI during resting state and a self-referential processing task. The baseline scan will also include a high-resolution structural sequence for neuronavigational purposes. Then, participants will receive 20 daily (5 days/week) sessions of rTMS to the VMPFC along with weekly assessments. Participants will undergo a repeated fMRI scan early in the course of treatment (after session 5) when we would expect neural changes to be evident but prior to any robust overall antidepressant effect, as well as at the end of the rTMS course (after session 20). Scores on the depression and rumination scales will be recorded prior to intervention and weekly thereafter. Contact with subjects will be conducted once via telephone at two weeks after the end of study intervention as an adverse event assessment. In the event that new or persistent adverse events felt to be related to the study intervention occur following the termination of study procedures, subjects may be brought in for further safety assessments.

研究类型

介入性

注册 (估计的)

20

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Indiana
      • Indianapolis、Indiana、美国、46202
        • Goodman Hall Neuroscience Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 70年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Diagnosis of unipolar major depressive disorder without psychotic features by the Mini-International Neuropsychiatric Interview (MINI) and confirmed by study psychiatrist
  • First depressive episode prior to age 50
  • Current moderate to severe depression, Hamilton Depression Rating Scale (HDRS) ≥17)
  • Failure to respond to ≥1 antidepressant medication at adequate dose and duration in the current depressive episode; (note: this criterion is designed to be consistent with the original 2008 FDA-labeled indication for TMS in Major Depressive Disorder, that specifies failure to respond to "one prior medication at or above the minimal effective dose and duration in the current episode" (https://www.accessdata.fda.gov/cdrh_docs/pdf8/K083538.pdf). ))
  • Off psychotropic medications OR on a stable dose of medication(s) for 6 weeks, and willing to remain on stable medication dosage throughout the study
  • Capacity to consent
  • Ability to safely receive MRI

Exclusion Criteria:

  • Actively/imminently suicidal, Quick Inventory of Depressive Symptomatology (QIDS) item 12 score >2)
  • Current depressive episode duration > 5 years
  • Presence of clinically significant psychiatric diagnoses other than unipolar, non-psychotic major depression, such as post-traumatic stress disorder (PTSD) or obsessive-compulsive disorder (OCD)
  • Evidence of cognitive impairment, Montreal Cognitive Assessment (MOCA) < 23)
  • Significant substance use disorder within past 6 months
  • New-onset psychotherapy and/or somatic therapy (e.g., light therapy) within 6 weeks of screening
  • Prior exposure to any form of TMS
  • Have participated in any clinical trial with an investigational drug or device within the past 6 weeks prior to screening
  • Failure to respond to Electroconvulsive therapy (ECT)
  • Any history of neurosurgery to treat a neurologic or psychiatric disorder (e.g. Vagus nerve stimulation, cortical stimulation, deep brain stimulation, or ablative surgery)
  • Unstable medical illness
  • Evidence or history of significant neurological disorder, including moderate-severe head trauma, stroke, Parkinson's disease or other movement disorder (except benign essential tremor)
  • Epilepsy
  • History of seizures (except juvenile febrile seizures or provoked seizures at the PI's discretion) or any condition/concurrent medication that could notably lower seizure threshold
  • Pregnancy or planned pregnancy during the study
  • Presence of cardiac pacemaker, cochlear implant, or other implanted electronic device
  • Any vision problem that will prevent them from seeing the adjectives presented inside the MRI scanner without glasses

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Active TMS

All participants will receive active TMS to the VMPFC for 20 sessions

rTMS delivered at 1 Hz for 1800 pulses over 30 minutes for 20 daily sessions, 5 days/week. Treatment will be directed to the ventromedial prefrontal cortex using each participant's structural MRI.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Functional Connectivity
大体时间:Before Transcranial magnetic stimulation (TMS) - immediately following TMS

Within-network functional connectivity of the default mode network during negative processing

Before Transcranial magnetic stimulation (TMS) - immediately following TMS
Rumination
大体时间:Before TMS- immediately following TMS

Scores on the Ruminative Response Scale (Range 22-88, with higher worse)

Before TMS- immediately following TMS

次要结果测量

结果测量
措施说明
大体时间
Overall Depression Scores
大体时间:Before TMS- immediately following TMS

Hamilton Depression Rating Scale (Range 0-52, with higher worse)

Before TMS- immediately following TMS

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Susan K Conroy, MD PhD、Indiana University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年1月2日

初级完成 (估计的)

2027年1月30日

研究完成 (估计的)

2027年1月30日

研究注册日期

首次提交

2024年7月8日

首先提交符合 QC 标准的

2024年7月15日

首次发布 (实际的)

2024年7月22日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • 13322
  • K12TR004415 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅